1-Minute Summary: Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO)

Expert Name
Dr Saied Ghadersohi

Ghadersohi S, Price CPE, Jensen SE, et al. Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO). J Allergy Clin Immunol Pract. 2020;8(7):2341-2350.e1. Chronic rhinosinusitis (CRS) is an inflammatory disease of the nasal airways and paranasal sinuses with a high disease burden [1,2]. Patient-reported outcome (PRO) instruments are measures of disease severity and symptom burden in…

1-Minute Summary: Altered Mitochondrial Functions and Morphologies in Epithelial Cells Are Associated With Pathogenesis of Chronic Rhinosinusitis With Nasal Polyps

Expert Name
Dr Young Hoon Yoon

Young HY, Sun HE, et al. Altered Mitochondrial Functions and Morphologies in Epithelial Cells Are Associated With Pathogenesis of Chronic Rhinosinusitis With Nasal Polyps. Allergy Asthma Immunol Res. 2020 Jul;12(4):653-668 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory disease of the nasal and paranasal sinus mucosa [1]. There are indications that the disease is associated with mitochondrial dysfunction,…

1-Minute Summary: A Network Meta-Analysis of Randomised Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children

Expert Name
Dr Theodore Rokkas

Rokkas T, et al. A network meta-analysis of randomized controlled trials on the treatment of eosinophilic esophagitis in adults and children. J Clin Gastroenterol 2020; published ahead of print. For eosinophilic esophagitis (EoE), apart from steroids [1], newer therapeutic interventions and relevant randomised controlled trials (RCTs) are available that have not been included in previous meta-analyses [2-6]. Network meta-analysis (NWM)…

COVID-19 and Implications for Type 2 Inflammatory Diseases

Expert Name
Prof. Georg Schett

Prof. Georg Schett is Chair of Internal Medicine 3 –Rheumatology and Immunology– at Friedrich-Alexander Universität (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen in Germany. His scientific work focuses on creating a better understanding of the molecular basis of immune-inflammatory diseases with rapid translation into clinical practice. His research work lead to the understanding of the phenomenon of LE-cells in 2007. Prof. Schett…

1-Minute Summary: Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline

Expert Name
Prof. Fernando Holguin

In 2014, the first guidelines for the treatment of severe asthma in children and adults were composed by the European Respiratory Society/American Thoracic Society (ERS/ATS) [1]. Since 2017, a multidisciplinary Task Force of asthma experts, co-chaired by Dr Fernando Holguin and Dr Andy Bush, has worked on an updated version. The Task Force made 6 recommendations that were not addressed…

Afbeelding met schermafbeelding Automatisch gegenereerde beschrijving

1-Minute Summary: EUFOREA Consensus on Biologics for CRSwNP with or without Asthma

Expert Name
Dr. Wytske Fokkens

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition of the sinonasal cavities [1-3]. It is frequently comorbid with asthma and both diseases share common underlying pathophysiological mechanisms driving the disease, including type 2 inflammation [3-9]. CRSwNP severely impacts quality of life and has a significant burden on society [10-12]. When symptoms are persistent or when there is…

1-Minute Summary: Biomarkers in asthma management: Time to move forward

Expert Name
Prof. Kjell Alving

Alving K, Diamant Z, Lucas S, et al. Point‐of‐care biomarkers in asthma management: Time to move forward Allergy. Allergy. 2020;75(4):995‐997. The Global Initiative for Asthma (GINA) report has directed clinical guidelines for asthma since 2014. Evidence comes from randomised controlled trials, but not from real-world or observational studies, which could be a limitation [1]. Asthma is a heterogeneous condition with…

Holistic View on Asthma

Expert Name
Prof. Zuzana Diamant

In the past 15 years, striking progress has been made in our understanding of the mechanisms underlying chronic inflammatory airway disease as well as the predisposing and interfering factors. These insights have resulted in a more holistic and personalised approach to the diagnosis and management of chronic inflammatory airway diseases including their comorbidities. At the annual congress of the European…

IL-1⍺ blockade: a new treatment option in AD

Expert Name
Prof. Alice Gottlieb

IL-1⍺ blockade is a novel interesting target in atopic dermatitis (AD). In a proof-of-concept study, an IL-1 blocker improved AD in all disease measures [1]. “The rationale behind targeting IL-1⍺ is that Th1 immunity plays a signifying role in adults with chronic AD,” said Prof. Alice Gottlieb (Icahn School of Medicine at Mount Sinai, USA). Under the influence of a…

A close up of a map Description automatically generated

JAK inhibition plus TCS lead to high clearance rates in AD

Expert Name
Prof. Kristian Reich

In addition to skin clearance, baricitinib in combination with topical corticosteroid (TCS) showed to be particularly effective in pruritus reduction and improvement of sleep in adult patients with moderate-to-severe atopic dermatitis (AD) [1]. Baricitinib is a selective Janus kinase (JAK) 1 and 2 inhibitor that has previously shown to be effective in moderate-to-severe AD when given as monotherapy. The BREEEZE-AD7…